Microba Life Sciences
- Short interest
- 0.10%
- +0.10 pp 30d
- as of 19 June 2026
- Reported shorts
- 700K
- Shares on issue
- 700.308M
Microba Life Sciences (MAP) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $14.8MM (source: ASX (Markit))vs $15.7M (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$20.7MM (source: ASX (Markit))vs −$14.9M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.035T (source: Derived: trailing 12 months at year end)vs −$0.033 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −5.8%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of 2026 Annual Report & Appendix 4E, 31 Aug 2026
Microba Life Sciences reported FY2026 revenue down 5.8% to $14.76 million, with a statutory net loss widening 38.7% to $20.72 million. No dividend was paid or declared. The company highlighted strong core testing revenue growth of 92% to $8.6 million, with a clean revenue base entering FY27 after completing the legacy phase-out.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 22 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- −140.4%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $14.8MM (source: ASX (Markit)) | $15.7M | $12.1M | $5.4M |
| Gross profit | n/a | $7.4M | $5.9M | $2.7M |
| Operating income | n/a | −$24.6M | −$26.8M | −$20.2M |
| EBITDA | n/a | −$10.5M | −$17.1M | −$11.0M |
| EBIT | n/a | −$14.9M | −$20.0M | −$12.7M |
| Interest expense | n/a | $103.9K | $18.6K | $16.4K |
| Pretax income | n/a | −$15.0M | −$20.0M | −$12.7M |
| Tax | n/a | −$106.6K | −$51.3K | $5.6K |
| NPAT | −$20.7MM (source: ASX (Markit)) | −$14.9M | −$19.9M | −$12.7M |
| Net interest income | n/a | $406.7K | $935.5K | $817.6K |
| EPS basic | −$0.035T (source: Derived: trailing 12 months at year end) | −$0.033 | −$0.049 | −$0.038 |
| EPS diluted | −$0.035T (source: Derived: trailing 12 months at year end) | −$0.033 | −$0.049 | −$0.038 |
| Shares | n/a | 515.0M | 447.9M | 364.6M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Q1 FY27 Quarterly Activities Report & Appendix 4CQuarterly Report20 Oct 2026via asx_announcements
- 2026 Annual Report & Appendix 4EAnnual Results31 Aug 2026via asx_announcements
- Q4 FY26 Quarterly Activities Report & Appendix 4CQuarterly Report16 Jul 2026via asx_announcements
- Details of Q4 FY26 Quarterly Report, Appendix 4C & WebinarQuarterly Report14 Jul 2026via asx_announcements
- Q3 FY26 Quarterly Activities Report & Appendix 4CQuarterly Report30 Apr 2026via asx_announcements
- Details of Q3 FY26 Quarterly Report, Appendix 4C & WebinarQuarterly Report28 Apr 2026via asx_announcements
- Appendix 4D & FY26 Interim ReportHalf Year Results26 Feb 2026via asx_announcements
- Q2 FY26 Quarterly Activities Report & Appendix 4CQuarterly Report29 Jan 2026via asx_announcements
- Details of Q2 FY26 Quarterly Report, Appendix 4C & WebinarQuarterly Report22 Jan 2026via asx_announcements
- Q1 FY26 Quarterly Activities Report & Appendix 4CQuarterly Report28 Oct 2025via asx_announcements
Showing 10 of 55 reports